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Abstract Transforming growth factor-L (TGF-L) signaling re-
lies on Smad-signaling pathway controlled in part by the pro-
teasome. Here we demonstrate that inhibition of the proteasome
function in mink epithelial cells accumulates both positive and
negative modulators of TGF-L signaling, phospho-Smad2 and
SnoN. Inhibition of the proteasome led to abrogation of TGF-
L target gene regulation in a gene-speci¢c manner. While reg-
ulation of p15Ink4b and myc by TGF-L are lost, PAI-1 induc-
tion, previously shown to occur in a Smad3-dependent manner,
was not a¡ected by treatment of the cells with the proteasom-
al inhibitor MG132. The results suggest that proteasomal ac-
tivity is required for TGF-L signaling in a gene-speci¢c
manner. , 2002 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Transforming growth factor-L (TGF-L) signaling is initiated
by binding of the ligand to type I and II receptor complex,
which activates the phosphorylation of signal transducers
Smad2 and Smad3 [1,2]. After phosphorylation, Smad2 and
Smad3 recruit a co-Smad, Smad4, to form heteromeric com-
plexes and migrate to the nucleus, where they either bind
directly to DNA or associate with other transcription factors
to regulate transcription of a large number of genes including
myc, junB and p15Ink4b cdk inhibitor (for review see [1,3]).
Several key transducers in the TGF-L-signaling pathway are
a¡ected by the ubiquitin^proteasome system. Proteasome
pathway is involved in destruction of Smad2 and Smad3
whose degradation switches o¡ TGF-L signaling [4^7]. Con-
versely, inhibitory Smad7, after binding to TGF-L receptors is
also subject to proteasomal degradation [8]. Interestingly,
SnoN (Ski-related novel protein N), a newly identi¢ed repres-
sor of TGF-L signal transduction pathway ([9,10], reviewed in
[11]), is also degraded via the ubiquitin^proteasome pathway,
mediated by anaphase^promoting complex (APC) or Smurf2
E3 ligases [12^14]. SnoN functions like a ‘switch’ in TGF-L
signal transduction: it interacts directly with the Smad2/3^
Smad4 complexes and represses their transactivation abilities,
thus shutting o¡ the signaling [15^17]. The capacity to inhibit
Smad2/3 signaling is shared by Ski, a SnoN-homolog and
prototype of the Ski-family of oncogenes ([16], for review
see [11]). The dissociation of SnoN from the Smads and its
degradation via the ubiquitin pathway allows the signaling to
pass through. Accordingly, TGF-L signal transduction is con-
trolled by the proteasome pathway both positively and neg-
atively: degradation of SnoN maintains the signal while deg-
radation of phosphorylated Smads turns it o¡. Regulation
between these two events ensures TGF-L signaling to continue
or stop at appropriate times corresponding to the environ-
mental cues of the cells. Considering the importance of the
proteasome-mediated degradation of TGF-L signaling mole-
cules, it is relevant to address the question whether TGF-L
signaling is maintained if the proteasome function is abro-
gated. Here, we inhibit the function of the ubiquitin^protea-
some pathway and demonstrate that the TGF-L-mediated
early signaling is intact in vivo in Mv1Lu mink lung epithelial
cells, but is abrogated at later timepoints in a gene-speci¢c
manner apparently through an increase of SnoN.
2. Materials and methods
2.1. Cells, cell culture and reagents
Mv1Lu mink lung epithelial cells (CCL64, American Type Cultured
Collection, Manassas, VA, USA) were maintained in Dulbecco’s
modi¢ed Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum (FCS) and were kept at 5% CO2 atmosphere at 37‡C. In
all assays, the cells were treated with 100 pM of TGF-L or 10 WM of
MG132 (MG, Z-Leu-Leu-Leu-CHO, A⁄nity Research Products Ltd.,
Mamhead, UK) in DMEM containing 10% FCS. TGF-L was puri¢ed
from outdated human platelets.
2.2. Antibodies
SnoN antibody used for immunoblotting and immuno£uorescence
(H-317) was from Santa Cruz Biotechnology (Santa Cruz, CA, USA)
and phospho-Smad2 antibody was a kind gift from Peter ten Dijke
and Carl-Henrik Heldin [18]. Smad2/3 antibody (610843) was from
BD Transduction Laboratories. Biotin-conjugated goat anti-rabbit,
goat anti-mouse and streptavidin antibodies were from DAKO
(Glostrup, Denmark). Goat anti-rabbit Alexa 594 or 488 were from
Molecular Probes.
2.3. Immunoblotting
Cells were lysed with 50 mM Tris^HCl bu¡er, pH 6.8, containing
100 mM dithiothreitol, 2% sodium dodecyl sulfate (SDS), and 10%
glycerol and DNA was sheared by sonication as described before [19].
Total cellular proteins were separated by SDS^polyacrylamide gel
electrophoresis and transferred to Immobilon-P membrane (Millipore,
Bradford, MA, USA). Immunoblotting with the indicated antibodies
was carried out as described before [20] followed by detection with
enhanced chemiluminescence (Amersham Life Sciences). Multi-Ana-
lyst program 1.0.2 (Bio-Rad) was used to quantitate the signals.
2.4. Immuno£uorescence staining
Cells grown on glass coverslips were ¢xed with 3.5% paraformal-
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dehyde in PBS for 20 min at room temperature and then permeabi-
lized with 0.5% Nonidet P-40 for 5 min. Coverslips were incubated
with anti-SnoN or anti-phospho-Smad2 antibody at 37‡C for 1 h
followed by incubation with either anti-rabbit Alexa 594 or 488 at
37‡C for another 1 h. Nuclei were counterstained with Hoechst 33258
(Sigma). The staining was visualized with Axioplan 2 MOT micro-
scope (Zeiss, Jena, Germany) equipped with appropriate ¢lters.
2.5. Northern analysis
Poly A+-RNA was isolated with GenElute1 Direct mRNA mini-
prep kit (Sigma, St. Louis, MO, USA). mRNA (2 Wg) was separated
on 1% agarose^formaldehyde gel and transferred to Hybond-Nþ
membrane in 20USSC (1USSC is 0.15 M NaCl plus 0.015 M sodium
citrate). mRNA was detected by probing with human p15INK4B,
myc, junB, PAI-1 or GAPDH fragments labeled with (Q-32P)dCTP
by random priming (Ready-to-Go, Pharmacia).
3. Results and discussion
3.1. Inhibition of the proteasome augments the levels of
phospho-Smad2
Since both positive and negative regulators of the TGF-L-
signaling pathway are controlled by ubiquitin-mediated deg-
radation, we wanted to analyze the cellular levels of Smad2
and SnoN, the primary e¡ectors of TGF-L signaling. Smad2 is
rapidly phosphorylated (phospho-Smad2) following the ligand
binding initiating the intracellular signaling cascade. The
phosphorylation is subsequently required for its degradation
through the proteasome pathway [1]. We treated Mv1Lu ep-
ithelial cells with physiologically relevant concentrations of
TGF-L known to elicit a growth inhibitory response within
12^16 h and analyzed the levels of phospho-Smad2 with or
without treatment of MG132, a speci¢c proteasomal inhibitor
that blocks the chymotryptic activity of the 26S proteasome.
TGF-L induced a rapid, 10-fold increase in the levels of phos-
pho-Smad2 as detected by immunoblotting (Fig. 1A,B) and
immuno£uorescence analyses (not shown). Increased levels of
phospho-Smad2 still persisted at a late timepoint (16 h)
though they had declined from the highest level of induction
observed at 4 h (Fig. 1A,B). Treatment of Mv1Lu cells with
MG132 gradually increased the phospho-Smad2 levels, and
by 16 h its level was increased by nine-fold (Fig. 1A,B). Com-
bination of TGF-L and MG132 during the treatment in-
creased the levels of phospho-Smad2 over that of TGF-L
treatment alone, and showed a marked increase at 16 h
(Fig. 1A,B). A similar change is visualized by immuno£uores-
cence showing a clear accumulation of phospho-Smad2 in
nucleus in TGF-L- and MG132-treated cells, indicating that
TGF-L signal transduction is intact in this respect (Fig. 3).
Total levels of Smad2/3 increased by two-fold as shown for
the 16 h timepoint in Fig. 1A.
3.2. MG132 increases SnoN and prevents TGF-L-mediated
downregulation at a late timepoint
Next, we analyzed the levels of SnoN, which is degraded
Fig. 1. MG132 modulates TGF-L e¡ects on phospho-Smad2.
Mv1Lu cells were treated with TGF-L (100 pM) and MG132 (10
WM) as indicated for the times shown. Total cell extracts were pre-
pared and phospho-Smad2 protein levels were analyzed by immuno-
blotting using an phospho-Smad2/3 antibody or an antibody detect-
ing total Smad2/3 (A). The signals were quantitated and the average
of two independent experiments with standard error are shown (B).
The amount of phospho-Smad2 in control cells was set as 1. Ctrl,
control; MG, MG132; p-Smad2, phospho-Smad2.
Fig. 2. MG132 increases SnoN levels and prevents TGF-L-mediated
downregulation. Total cell extracts of Mv1Lu cells treated with
TGF-L and MG132 as indicated were prepared and SnoN protein
levels were analyzed by immunoblotting (A) followed by quantita-
tion of the signals (B). The results are the average of two indepen-
dent experiments with standard error shown. Ctrl, control; MG,
MG132.
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through the proteasome in both Smad-dependent and -inde-
pendent manner [9,12^14]. As described previously [9], TGF-L
rapidly reduced SnoN protein level within 1 h and SnoN was
maintained low throughout the follow-up as shown both by
immunoblotting and immuno£uorescence (Figs. 2A,B and 3).
Treatment of the cells by MG132 caused a progressive in-
crease in SnoN levels up to 16 h, indicating that it is under-
going proteolytic degradation also in the absence of TGF-L
signaling (Figs. 2A,B and 3; refs. [9,14]). MG132-treatment of
the cells did not prevent the initial decrease of SnoN by
TGF-L within 2 h, but completely blocked the TGF-L-medi-
ated decrease of SnoN observed 16 h after addition of TGF-L
(Figs. 2A,B and 3). This suggests that MG132 treatment has
relatively little e¡ect on TGF-L signaling components early on
after its addition, whereas at later timepoints it possibly can
abrogate TGF-L signaling by inhibiting SnoN downregula-
tion.
Earlier reports on regulation of SnoN by TGF-L have in-
dicated that the rapid decrease of SnoN is mediated through
proteasomal degradation [12^14,16], but that longer TGF-L
treatments increase SnoN levels through an increase of SnoN
mRNA [10]. Transcriptional induction of a signaling repressor
is reminiscent to that of p53 induction of its E3-ubiquitin
ligase and thus repressor, Mdm2, generating a succession of
rapid oscillations in the levels of p53 and mdm2 [21]. Thus
when signaling is permissive, i.e. levels of SnoN are low, an
increase in SnoN and its binding to Smad2/3 will switch o¡
the signal until SnoN is degraded below a threshold level.
Analysis of endogenous phospho-Smad2 and SnoN, as dem-
onstrated here, indicated that abrogation of the proteasome
activity appears mainly to a¡ect late (16 h) TGF-L-regulated
events by maintaining elevated levels of phospho-Smad2 as
well as SnoN. Therefore it was pertinent to address whether
TGF-L signaling is functional under these conditions.
3.3. Downregulation of the proteasome allows early TGF-L
signaling but abrogates late TGF-L e¡ects in a
target-gene-speci¢c manner
We carried out Northern analyses of genes regulated by the
TGF-L^Smad pathway, myc [22], junB [23], PAI-1 [24] and
p15 [25]. Of these, junB and PAI-1 are rapid early response
genes for TGF-L [26^28], p15 is induced with slower kinetics
[29] and c-myc is downregulated by TGF-L [30]. The results
showed that TGF-L induction of junB and p15 was intact 2 h
after addition of MG132 (three- and 1.5-fold inductions, re-
spectively), but p15 mRNA was somewhat diminished by 4 h
(Fig. 4A,B). Though initial induction of PAI-1 in the presence
of MG132 was lower than by TGF-L alone (24 vs. 12-fold),
Fig. 3. MG132 increases the levels of phospho-Smad2 and SnoN. Mv1Lu cells were treated with TGF-L and MG132 for 16 h followed by im-
muno£uorescence analysis for phospho-Smad2 and SnoN. DNA was stained by Hoechst 33258. A representative result of three independent ex-
periments is shown. Ctrl, control; MG, MG132.
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the inductions were comparable by 4 h (Fig. 4A,B). However,
MG132 abrogated TGF-L-mediated induction p15 by 16 h,
whereas PAI-1 induction was maintained (Fig. 4). Due to
the nature of junB being an early response gene, its induction
by TGF-L was transient and no longer detectable at the late
timepoint. Downregulation of myc by TGF-L was observed at
late timepoints and this e¡ect was completely abrogated by
MG132 (Fig. 4). The results indicate that treatment of the
cells with the proteasomal inhibitor allows substantial
TGF-L signaling to pass through at least initially, but that
the signaling is disrupted late after inhibition of the protea-
some function in a target-gene-speci¢c manner.
The regulation of TGF-L target genes via Smad-signaling
pathway can utilize either Smad2 or Smad3-dependent events
or poses a requirement for the presence of both Smads. Piek
et al. [31] show by using Smad2 or -3 null cells, that while
TGF-L induction of p15 requires both Smad2 and Smad3,
PAI-1 and junB require only Smad3. Accordingly, our obser-
vation that downregulation of the proteasome will allow
TGF-L induction of PAI-1, but not p15, is suggestive that
Fig. 4. TGF-L regulation of gene responses is modulated by proteasome inhibition. Mv1Lu cells were treated with TGF-L and MG132 as indi-
cated for the times shown and the regulation of the indicated genes was analyzed by Northern assays (A). GAPDH was used as loading con-
trol. The signals were quantitated by Multi-Analyst and normalized against GAPDH levels. Relative levels on the basis of three independent
experiments are shown (B).
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Smad3 pathway is intact, whereas that of Smad2-dependent
pathway is abrogated by MG132. Smad2 is degraded through
the proteasome in a Smurf2-dependent manner [5,7], and
Smad3 through ROC1 [32]. SnoN, on the other hand, is tar-
geted to the proteasome both by Smad2^Smurf2 complex and
by Smad3^APC complex. Therefore, an increase in SnoN lev-
els is projected to block both Smad2 and Smad3-dependent
signaling depending on the relative ratio of the proteins.
Though Smad7^TGF-L receptor complex is also degraded
by the proteasome [8], a possible increase in Smad7 is unlikely
to inhibit Smad2-related signaling as high levels of phospho-
Smad2 are still detected in the nucleus.
In response to proteasome inhibition we observe signi¢cant
increases in both phospho-Smad2 as well as SnoN. A poten-
tial selectivity of SnoN towards either Smad2 or Smad3 may
arise from di¡erences in the relative levels of the respective
proteins or other factors determining their interactions and
thus the ability of SnoN to repress Smad-dependent transcrip-
tion. The block of TGF-L signaling towards only speci¢c tar-
get genes suggests that proteasomal activity is required selec-
tively in the TGF-L-signaling pathway.
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